THERAPEUTIC FOCUS
RESEARCH & DEVELOPMENT
PUBLICATIONS
PARTNERING
INVESTOR RELATIONS
Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. Vascepa is the first and only pure EPA omega-3 fatty acid that has been clinical proven to significantly reduce TG levels without increasing LDL-C levels and provide a spectrum of additional lipid treatment benefits with a tolerability and safety profile similar to placebo. For more information about Vascepa visit www.vascepa.com.

See important safety information about Vascepa

See full prescribing information for Vascepa

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

This page was last updated January 28, 2013.